SRC and cancer: Dasatinib combined with paclitaxel treatment downregulated p-Src expression in cancer cells (23.3 vs. 31.0% in A2780 cells and 21.3 vs. 48.7% in HO8910 cells), as compared with dasatinib treatment alone (Figs. 4B and C).